Profile data is unavailable for this security.
About the company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
- Revenue in USD (TTM)411.33m
- Net income in USD271.17m
- Incorporated1996
- Employees159.00
- LocationInnoviva Inc1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME 94010United StatesUSA
- Phone+1 (650) 238-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.inva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 6.31m | -425.87m | 1.28bn | 143.00 | -- | 30.59 | -- | 203.02 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Collegium Pharmaceutical Inc | 780.57m | 62.87m | 1.32bn | 423.00 | 24.32 | 4.37 | 4.57 | 1.69 | 1.71 | 1.71 | 20.54 | 9.51 | 0.4702 | 8.30 | 3.55 | 1,845,312.00 | 3.79 | 3.89 | 5.30 | 5.96 | 59.35 | 56.32 | 8.05 | 8.34 | 1.48 | 2.65 | 0.7285 | 0.00 | 23.62 | 20.28 | -9.13 | 18.64 | -65.83 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.52bn | 165.00 | -- | 6.37 | -- | 35.86 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.66bn | 524.00 | -- | 4.35 | -- | 4.14 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.67bn | 293.00 | 10.65 | 1.92 | 9.08 | 1.92 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.69bn | 897.00 | 46.13 | 3.34 | 12.93 | 2.04 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Innoviva Inc | 411.33m | 271.17m | 1.69bn | 159.00 | 7.38 | 1.45 | 5.43 | 4.11 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.70bn | 8.10k | -- | 0.5784 | -- | 0.3994 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Sarepta Therapeutics Inc | 2.20bn | -842.79m | 1.71bn | 1.37k | -- | 1.50 | -- | 0.7793 | -8.44 | -8.44 | 21.50 | 10.87 | 0.6012 | 1.01 | 4.40 | -- | -23.05 | -12.81 | -30.73 | -15.87 | 61.81 | 77.84 | -38.34 | -30.61 | 1.48 | -853.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | -- | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.74bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Vericel Corp | 276.26m | 16.52m | 1.79bn | 398.00 | 134.30 | 5.05 | 63.64 | 6.50 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.87bn | 10.00k | 10.03 | 2.49 | 3.42 | 0.3011 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.89bn | 300.00 | 6.83 | 3.23 | 6.16 | 6.68 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.98bn | 382.00 | -- | 42.21 | 145.07 | 7.94 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
Data as of Mar 03 2026. Currency figures normalised to Innoviva Inc's reporting currency: US Dollar USD
52.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.46m | 12.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.34m | 9.82% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 4.21m | 5.63% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 4.18m | 5.60% |
| Sarissa Capital Management LPas of 31 Dec 2025 | 2.82m | 3.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.80m | 3.74% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 2.36m | 3.15% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 2.24m | 3.00% |
| Systematic Financial Management LPas of 31 Dec 2025 | 2.11m | 2.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.75m | 2.34% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
